title: An update on the use of ophthalmic ketorolac tromethamine 0.4%.
abstract: Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.
authors.affiliation: Ophthalmic Consultants of Long Island, 2000 North Village Avenue, Rockville Centre, New York 11570, USA. hankcornea@aol.com
authors.forename: Henry D
authors.initials: HD
authors.lastname: Perry
authors.forename: Eric D
authors.initials: ED
authors.lastname: Donnenfeld
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D005128:Eye Diseases / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D020911:Ketorolac Tromethamine / Q000008:administration & dosage*; D011453:Prostaglandins / Q000096:biosynthesis; D014606:Uveitis, Anterior / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011453:Prostaglandins; D020911:Ketorolac Tromethamine